Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

Wolf, John E.; Shander, Douglas; Huber, Ferdinand; Jackson, Joseph; Lin, Chensheng; Mathes, Barbara; Schrode, Kathy

doi:10.1111/j.1365-4632.2006.03079.x

Cited by 120 publications

(84 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some cases of mild hirsutism localised on the face, an alternative may be the topical application of a 13.9% eflornithine (an irreversible inhibitor of L-ornithine decarboxylase) cream, which may reversibly slow facial hair growth in many hirsute women. However, it does not remove hair (271).…”

Section: Therapeutic Approach To the Hyperandrogenic Phenotypementioning

confidence: 99%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

576

492

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.

show abstract

Section: Therapeutic Approach To the Hyperandrogenic Phenotypementioning

confidence: 99%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

576

492

View full text Add to dashboard Cite

show abstract

“…The cream is well tolerated and, in combination with laser epilation, is more effective than hair removal methods used alone. 25 Another goal of therapy in PCOS is to reduce obesity, where in addition to lifestyle modification, diet and pharmacological therapy with metformin, surgical methods have been applied. It has been demonstrated that bariatric procedures for the treatment of obesity greatly improve the profile of patients with PCOS by preventing metabolic syndrome; reducing body weight, blood pressure and the risk of cardiovascular diseases; restoring normal function of the hypothalamic-pituitary axis; improving reproductive function; and also, as demonstrated by Eid et al, normalizing blood pressure in approximately 78% of treated patients with previous hypertension.…”

Section: Currently Applied Treatmentmentioning

confidence: 99%

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

Bednarska¹,

Siejka²

2017

Adv Clin Exp Med

227

148

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is currently the leading cause of menstrual complications in women. It is characterized by clinical and/or biochemical hyperandrogenism, ovulation abnormalities and the presence of enlarged and/or polycystic ovaries in ultrasound images (12 or more small bubbles located circumferentially and/or ovarian volume > 10 mL). It is often comorbid with hyperinsulinemia, dyslipidemia, overweight or obesity, and is a risk factor for the development of diabetes and cardiovascular diseases (CVDs). The treatment of patients with PCOS depends on the prevailing symptoms. The aim of this paper is to present the etiopathogenesis, clinical and biochemical implications, and non-pharmacological and pharmacological treatment options -those approved by worldwide scientific organizations as well as new therapies whose initial results are encouraging enough to prompt researchers to explore them further.

show abstract

“…Eflornithine is an irreversible inhibitor of L-ornithine decarboxylase, which is involved in the regulation and differentiation of the hair follicle (55). Topical administration of eflornithine may reversibly slow facial hair growth in many hirsute women (56), but it does not remove hair. Although its systemic absorption is very low, it may cause skin irritation.…”

Section: Topical Medicationmentioning

confidence: 99%

THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome

Pasquali

Gambineri

2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Hirsutism is a common medical complaint among women of reproductive age, and it affects the majority of women with the polycystic ovary syndrome (PCOS). Increased rate of androgen production and its availability in tissue represent the main pathophysiological mechanisms responsible for hirsutism. In addition, androgens may be generated de novo in the hair follicle; therefore, circulating androgen levels do not quantify the real exposure of the hair follicle to androgens, as a quota is locally generated. Hirsutism is a clinical sign and not a disease in itself; its presence does not therefore necessarily require treatment, particularly in mild-to-moderate forms, and when an affected woman does not worry about it. Physicians should decide whether hirsutism is to be treated or not by evaluating not only the severity of the phenomenon but also the subjective perception of the patient, which does not necessarily correspond to the true extent of hair growth. In any case, a physician should manage a woman with hirsutism only on the basis of a diagnosis of the underlying cause, and after a clear explanation of the efficacy of each therapeutic choice. Cosmetic procedures and pharmacological intervention are commonly used in the treatment of hirsutism and are discussed in this paper. Importantly, there are different phenotypes of women with hirsutism and PCOS that may require specific attention in the choice of treatment. In particular, when obesity is present, lifestyle intervention should be always considered, and if necessary combined with pharmacotherapy.

show abstract

Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

Cited by 120 publications

References 12 publications

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

The pathogenesis and treatment of polycystic ovary syndrome: What’s new?

THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome

Contact Info

Product

Resources

About